Description

6-Diazo-5-oxo-L-nor-Leucine, 5000mg

(commonly referred to as L-6-Diazo-5-oxonorleucine or DON) acts as a glutamine antagonist, effectively inhibiting the catabolic effects associated with glutamine. This compound demonstrates significant anticancer properties, particularly in the context of pancreatic cancer, and has been shown to diminish the self-renewal capabilities and metastatic potential of tumor cells. Additionally, 6-Diazo-5-oxo-L-nor-Leucine exhibits both antibacterial and antiviral activities.

6-Diazo-5-oxo-L-norleucine (DON) is a known glutamine antagonist that was first isolated from a sample of Peruvian soil collected from the Streptomyces genus. This diazo compound is produced from lysine through the action of three specific enzymes in bacteria. Initially characterized in 1956 by Henry W Dion and colleagues, DON was noted for its potential application in cancer treatment, a possibility that has since been supported by various animal studies demonstrating its antitumor properties. Although DON underwent testing as a chemotherapeutic agent in numerous clinical trials, it has not received regulatory approval. More recently, research in 2019 highlighted DON’s ability to induce tumor cell death while alleviating disease symptoms and enhancing overall survival in mice with late-stage experimental glioblastoma when paired with a ketogenic diet that incorporates calorie restriction.

More

Publications: PubMed

Certificates:  COA